Azithromycin ophthalmic in-situ gel and preparation method thereof

A technology of azithromycin and in-situ gel, which is applied in the direction of medical preparations with non-active ingredients, medical preparations containing active ingredients, and pharmaceutical formulations. To achieve excellent bioadhesion, improve patient compliance, and improve bioavailability

Inactive Publication Date: 2018-03-30
沈小玲
View PDF9 Cites 10 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0006] In the ophthalmic drug delivery system, the traditional ophthalmic drug delivery form - eye drops, its principle of action is that the drug will be delivered with the secretion of tears after dripping into the ocular surface, which has the advantage of uniform drug distribution, but because the tear fluid in the conjunctival sac is not Stopped secretion and rapid elimination from the nasolacrimal duct, there are problems such as short residence time and low bioavailability, which are related to the very effective protection mechanisms of the eyes such as tearing and blinking reflex, so that the medicine dripped into the eye can quickly pass from the cornea The anterior area is eliminated, the contact time with the cornea is only about 1-2 minutes, and the bioavailability of the eye is generally less than 10%
In addition, a large amount of drugs enter the nasal cavity or digestive tract through the nasolacrimal duct and are finally absorbed systemically, which increases the risk of side effects and toxicity
Another traditional ophthalmic dosage form - eye ointment, which is usually made of petroleum jelly as a base, although it can provide a longer drug residence time, but it has a strong greasy feeling, which can cause blurred vision and eyelid crusting after use problems, and usually only at bedtime
The ophthalmic gel is a carrier with a hydrophilic polymer, which has good biocompatibility. It is in a semi-solid state, which can prolong the ac

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Azithromycin ophthalmic in-situ gel and preparation method thereof
  • Azithromycin ophthalmic in-situ gel and preparation method thereof
  • Azithromycin ophthalmic in-situ gel and preparation method thereof

Examples

Experimental program
Comparison scheme
Effect test

Example Embodiment

[0036] Example 1

[0037] An azithromycin ophthalmic in situ gel, which comprises the following components by weight percentage of raw materials:

[0038]

[0039] Preparation:

[0040] 1) Dissolving citric acid and sodium citrate with water for injection, the amount of water for injection is 50% to 80% of the total water for injection, and then adding azithromycin, carboxylated chitosan, L-cysteine, Mannitol and benzalkonium chloride were continuously stirred and dissolved, then the prescribed amount of poloxamer 407 and poloxamer 188 were added, stirred evenly, and refrigerated at 4°C overnight to allow it to swell and dissolve slowly to obtain a clear, non-toxic Agglomerate, evenly dispersed solution, adjust the pH to 6.5 with sodium hydroxide pH regulator, filter and sterilize through a 0.22 μm microporous membrane to form solution I, and set aside;

[0041] 2) Weigh the prescribed amount of sodium alginate and hypromellose, slowly add to the heated water for injectio...

Example Embodiment

[0043] Example 2

[0044] An azithromycin ophthalmic in situ gel, which comprises the following components by weight percentage of raw materials:

[0045]

[0046] Preparation:

[0047] 1) Dissolving citric acid and sodium citrate with water for injection, the amount of water for injection is 50% to 80% of the total water for injection, and then adding azithromycin, carboxylated chitosan, L-cysteine, Mannitol and benzalkonium chloride were continuously stirred and dissolved, then the prescribed amount of poloxamer 407 and poloxamer 188 were added, stirred evenly, and refrigerated at 4°C overnight to allow it to swell and dissolve slowly to obtain a clear, non-toxic Agglomerate, evenly dispersed solution, adjust the pH to 6.5 with sodium hydroxide pH regulator, filter and sterilize through a 0.22 μm microporous membrane to form solution I, and set aside;

[0048] 2) Weigh the prescribed amount of sodium alginate and hypromellose, slowly add to the heated water for injectio...

Example Embodiment

[0050] Example 3

[0051] An azithromycin ophthalmic in situ gel, which comprises the following components by weight percentage of raw materials:

[0052]

[0053] Preparation:

[0054] 1) Dissolve citric acid and sodium citrate with water for injection, the amount of water for injection is 50-80% of the total amount of water for injection, and then add azithromycin, chitosan, L-cysteine, mannitol and Benzalkonium chloride, stir continuously to dissolve, then add the prescribed amount of poloxamer 407 and poloxamer 188, stir well, refrigerate overnight at 4°C, let it swell and dissolve slowly, and obtain a clear, lump-free solution 1. For the uniformly dispersed solution, adjust the pH to 6.5 with sodium hydroxide pH regulator, filter and sterilize through a 0.22 μm microporous membrane to form solution I, and set aside;

[0055] 2) Weigh the prescribed amount of sodium alginate and hypromellose, slowly add to the heated water for injection, the amount of water for injectio...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses azithromycin ophthalmic in-situ gel. The azithromycin ophthalmic in-situ gel comprises the following components in percentage by weight: 0.1 to 5 percent of azithromycin, 0.05to 5 percent of cationic polysaccharide, 0.05 to 5 percent of sodium alga acid, 10 to 30 percent of poloxamer 407, 0.1 to 15 percent of poloxamer 188, 0.05 to 5 percent of cosolvent and buffer salt thereof, 0.01 to 5 percent of a tackifier, 0.01 to 5 percent of an antioxidant, 0.1 to 10 percent of an osmotic pressure regulator and 0.001 to 2 percent of a preservative. The prepared azithromycin ophthalmic in-situ gel still has proper solution-gel phase conversion ability when being used and diluted by tear, has excellent mucous membrane permeability and biological adhesive force, overcomes thedefects in the prior art, increases the ocular bioavailability of the medicine, improves corneal permeability, reduces eye irritant irritation and improves compliance of patients. The invention also discloses a preparation method of the gel, wherein the process is simple.

Description

technical field [0001] The invention relates to the field of ophthalmic drugs, in particular to an ophthalmic gel. Background technique [0002] Bacterial conjunctivitis is the most common infection. It is widely spread among different countries, races, ages and genders. It is easy to infect in densely populated areas such as kindergartens and schools. Although it has self-healing properties, it is resistant to infection Treatment can shorten the course of the disease, prevent infection, and reduce complications. Gram-positive Staphylococci, Streptococcus pneumoniae, and Haemophilus influenzae were the most common pathogens. Acute bacterial conjunctivitis is a highly contagious acute conjunctival inflammation that occurs mainly in summer and autumn and uses bacteria as the pathogen. It is the most frequently encountered eye disease in daily ophthalmology first visits. Bacterial keratitis and conjunctivitis often cause varying degrees of damage to eye tissues, sometimes wit...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K9/06A61K31/7052A61K47/36A61K47/10A61K47/12A61K47/38A61K47/18A61P31/04A61P27/02
CPCA61K9/0048A61K9/06A61K31/7052A61K47/10A61K47/12A61K47/183A61K47/36A61K47/38
Inventor 沈小玲王倩何华英
Owner 沈小玲
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products